340B PATIENTS Act of 2025

1) What happened: HR4581, the 340B PATIENTS Act of 2025, was introduced in the House on July 22, 2025, by Rep. Matsui (D-CA) with 19 cosponsors. It was referred to the House Committee on Energy and Commerce. An identical companion bill, S2372, was introduced in the Senate and referred to the Health, Education, Labor, and Pensions Committee. The bill has seen no further floor action in either chamber since referral. Status is early-stage with low legislative velocity. 2) The money trail: This bill authorizes NO funding. It is a policy clarification bill that would amend the Public Health Service Act to explicitly prohibit drug manufacturers from placing conditions on 340B drug pricing based on whether a drug is dispensed through a contract pharmacy. The economic impact is defensive — it protects existing revenue flows rather than creating new ones. There is no appropriation mechanism. The bill does not create a new spending program or tax credit. 3) Structural winners and losers: Winners are retail pharmacy chains with large contract pharmacy networks (CVS, Walgreens) and drug wholesalers (McKesson, Cardinal Health) that service the 340B distribution chain. Losers would be drug manufacturers (Eli Lilly, Pfizer, Merck, Johnson & Johnson, AbbVie — not listed as tickers because the impact is diffuse and speculative at this stage) who have sought to restrict contract pharmacy arrangements due to alleged duplicate discounts and diversion. The bill language explicitly prohibits manufacturers from refusing to sell 340B-priced drugs based on dispensing location. 4) Competitive landscape: The 340B program is a $50B+ annual market (as of recent estimates). Contract pharmacy relationships have been the subject of litigation between manufacturers and the HHS Office of Inspector General. This bill is a response to manufacturer-imposed restrictions on contract pharmacy dispensing. If enacted, it solidifies the current status quo where covered entities can use multiple contract pharmacies. Without enactment, the legal landscape remains fragmented. 5) Timeline: The bill is at step 1 of a multi-step process. It must pass the House Energy and Commerce Committee, the full House, the Senate HELP Committee, the full Senate, and be signed by the President. With a Democratic sponsor and no Republican cosponsors listed in the enrichment data (the cosponsors listed in the bill introduction are all Democrats), bipartisan passage is uncertain. The 119th Congress has a Republican House majority and Republican Senate majority. The probability of passage in its current form is low in the near term. No recent actions since July 2025 indicate stalled momentum.